Famciclovir Articles
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Teva gets temporary halt on Famvir sales
17 September 2007
Novartis denied prelim injunction against Teva
17 September 2007
FDA OKs Teva's generic Famvir
3 September 2007
TAP's to co-promote Novartis' Famvir in USA
9 October 2006
Novartis' Famvir gets FDA approval
7 August 2006
Strong results for Novartis' Famvir
13 March 2006
GSK restructuring its R&D to boost productivity
22 February 2001
Chinese pharma sales, other industry data
6 February 2001
Novartis completes SB antiviral buy
4 January 2001
GlaxoSmithKline on December 27?
13 December 2000
Glaxo Wellcome/SmithKline Beecham merger still dogged by FTC demands
16 November 2000
GW/SB merger delayed until end of year
11 September 2000
SB sells Kytril, Famvir and Vectavir for $2.9bn
31 August 2000
GW pulls out of one Cantab herpes deal
18 August 2000
GW and SB being made to wait by FTC
16 June 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
SB drops development of idoxifene in osteoporosis
21 April 1999
Currency impact lifts SmithKline Beecham
20 April 1999
Medeva Has Heavy Reliance On Hepagene
4 December 1998
Cantab On Track To Being A Fully Integrated Company
3 December 1998
AASLD Conference - Focus On HCV/HBV By Lehman
1 December 1998
Adefovir Shows High Potency In Hepatitis B
11 November 1998
Famvir Plus Zadaxin Beneficial In HBV
5 November 1998
Solid Third Quarter At SB Thanks To New Products
20 October 1998
Currency And Flu Factors Hold Back SB Results
22 July 1998
Rosiglitazone Success In Phase III Boosts SB
18 June 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
SB's 1st-Quarter Impacted Again By Strong Sterling
22 April 1998
SmithKline Shares Drop On R&D Presentation
16 April 1998
Famvir Trial To Test Latency Prevention
15 April 1998
World Antiviral Market Forecasts To 2005
20 February 1998
Currency Hits SmithKline Beecham Sales And Profits
17 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
Strong Sterling Hits 3rd Qtr Profits At SB
22 October 1997
Famvir Potential Grows With New Data
15 October 1997
UK Approves Famvir's New Indication
26 May 1997
Investors Impressed With Glaxo Wellcome Pipeline
12 May 1997
Penciclovir Launched In USA
5 May 1997
Lamivudine Improves Liver Histology In Hepatitis B
21 April 1997
UK Rx Medicines Code Of Practice Report
20 January 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
Good Efficacy With SB's Famvir
18 November 1996
SB's Famvir "More Effective" Than Aciclovir
4 November 1996
New Hepatitis Treatments Highlighted At ICAAC
7 October 1996
Solvay Pharma And SB To Copromote Famvir
19 August 1996
SmithKline Beecham: A Leader In Spanish Market
19 August 1996
Global Branding Is A Must For Pharmaceuticals
12 August 1996
First Launch Of SB's Cold Sore Drug Penciclovir
10 June 1996
Antivirals "Now 9% Of Anti-Infectives Market"
11 March 1996
SmithKline Beecham Gets Second Indication For Famvir In The USA
18 December 1995
Treatment Of Chronic Hepatitis: New Options
4 December 1995
UK Prescription Medicine Code Of Practice Review
4 December 1995
SmithKline Beecham Meets Expectations In 1995 3rd Qtr
30 October 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
UK Code Of Practice Amendments, New Report
25 September 1995
European Stock Comment
25 September 1995
Famvir Gains Once-Daily Product license
18 September 1995
Interest Expenses, Currency Hit SB's Results
31 July 1995
FDA Approves Glaxo Wellcome's Valtrex
3 July 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
SB Files US Famvir sNDA For Herpes
29 May 1995
EUROPEAN STOCK COMMENT
8 May 1995
Valtrex Launched In Sweden; Genital Herpes Data
3 April 1995
UK Code Authority May Become Self-Supporting
20 March 1995
For SmithKline Beecham 1994 Was "Successful Year"
27 February 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
Valtrex Launched In Its First Markets
6 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
FDA C'tee Gives Thumbs Down For OTC Zovirax
23 January 1995
Fast FDA Approvals Of User-Fee NMEs In 1994
16 January 1995
Highlights Of SmithKline's R&D Portfolio
2 January 1995
Burroughs Wellcome Outlook Reviewed
19 December 1994
Analysts Upgrade SmithKline Beecham
31 October 1994
SB Sales Jump 8%, Fuelled By New Drugs
24 October 1994
New Data On Antiherpetics Presented At ICAAC
17 October 1994
UK Code Of Conduct Quarterly Review
17 October 1994
Wellcome: Gloves Off In Antiviral Battle
5 September 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
US Launch For SB's Famvir
8 August 1994
Four-Month Results At Wellcome As Expected
25 July 1994
SB Lifts 2nd Qtr Earnings 20%
25 July 1994
SB Sets US Price For Famvir At Same Level As Zovirax
18 July 1994
Wellcome Files First PLAs for Valaciclovir
18 July 1994
Europe Stock Comment
18 July 1994
US APPROVAL FOR SB'S FAMCICLOVIR
11 July 1994
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
